Investigations
Allianz SE
Allianz SE’s Ineffective Internal Controls Allowed its Subsidiary to Engage in Substantial Fraudulent Activity
February 1, 2023
THE NEWSROOM
Search
Categories
Archives
Investment Monitoring From Robbins LLP
To ensure your financial investments are being managed honestly, enroll in Stock Watch, our free investment monitoring service for individual and institutional investors.
Investigations
Invivyd, Inc. f/k/a Adagio Therapeutics, Inc.
Invivyd, Inc. (IVVD) Misled the Public Regarding the Viability and Efficacy of its Lead Drug Candidate ADG20 and the Drug’s Ability to Neutralize the COVID-19 Omicron Variant
February 1, 2023
Investigations
Argo Blockchain plc
Argo Blockchain plc (ARBK) Failed to Disclose Material Relevant Information in Connection with its Registration Statement in Support of its IPO
January 27, 2023
Investigations
Sotera Health Company
Sotera Health Company’s (SHC) EtO Processing Emitted Massive Toxins and Caused Cancer in People Living in the Communities Near its Facilities
January 25, 2023
Robbins LLP News
CHIPS Act of 2022
The CHIPS Act, or the Creating Helpful Incentives to Produce Semiconductors for America Act, is a legislation that aims to boost the production of semiconductors.
January 24, 2023
Investigations
Fate Therapeutics, Inc.
Fate Technologies, Inc. (FATE) Misrepresented the Impact of the Janssen Collaboration Agreement on Fate’s Long-Term Clinical and Commercial Profitability
January 24, 2023
Investigations
Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc. (YMAB) Misrepresented the Viability and Efficacy of its Lead Drug Candidate
January 20, 2023
Investigations
Latch, Inc.
Latch, Inc. (LTCH) f/k/a TS Innovation Acquisitions Corp. (TSIA) Issued a False and Misleading Registration Statement in Connection with its Merger
January 13, 2023
Robbins LLP News
The U.S. Securities and Exchange Commission is Busy at Work
The SEC is Making Changes in 2023
January 11, 2023
